First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia

被引：6
|
作者：
Argyropoulos, Kimon V. [1 ]
Lia, M. [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Program Immunol, 408 East 69th St, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, 1275 York Ave, New York, NY 10065 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 05期
关键词：
Waldenstrom macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors; B-CELL-RECEPTOR; ATRIAL-FIBRILLATION; GENE REARRANGEMENT; SOMATIC MUTATION; CLINICAL-TRIAL; IBRUTINIB USE; ACTIVATION; BTK; RESISTANCE; MYD88;
D O I：
10.1016/j.hoc.2018.05.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this article.
引用
收藏
页码：853 / +
页数：13
相关论文
共 50 条
  • [1] First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia (vol 32, pg 853, 2018)
    Palomba, M. Lia
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 33 (01) : XIII - XIII
  • [2] Second-generation inhibitors of Bruton tyrosine kinase
    Wu, Jingjing
    Liu, Christina
    Tsui, Stella T.
    Liu, Delong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [3] Second-generation inhibitors of Bruton tyrosine kinase
    Jingjing Wu
    Christina Liu
    Stella T. Tsui
    Delong Liu
    [J]. Journal of Hematology & Oncology, 9
  • [4] First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia: A systematic review and meta-analysis
    Abushukair, Hassan
    Syaj, Sebawe
    Ababneh, Obada
    Qarqash, Aref
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Al Hadidi, Samer
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (07) : 942 - 950
  • [5] Bruton tyrosine kinase inhibitors for Waldenstrom macroglobulinemia: A review
    Moore, Donald C.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (08) : 1993 - 1999
  • [6] Bruton tyrosine kinase inhibitors in the management of Waldenstrom macroglobulinemia
    Castillo, Jorge J.
    Buske, Christian
    Trotman, Judith
    Sarosiek, Shayna
    Treon, Steven P.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : 338 - 347
  • [7] The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstrom's Macroglobulinemia
    Khan, Abdullah Mohammad
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (05):
  • [8] First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
    Oehler, Vivian G.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 228 - 236
  • [9] Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma
    Lu, Jessie
    Do, Bryan
    Primeaux, Brian
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [10] First-generation vs second-generation antihistamines
    Aelony, Y
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (17) : 1949 - 1949
12345